Agreement builds on PharmaJet’s strategy to be the best-in-class delivery system for novel DNA- and RNA-based vaccines and immunotherapies usin...
First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date - - Trial funded...
Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel imm...
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispeci...
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-rel...
Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for th...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumo...
EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advan...
HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, announced that...
SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...
Metsera, Inc. announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leadin...
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule all...
Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced that the company has entered into a license, development and commercialization agreem...
© 2025 Biopharma Boardroom. All Rights Reserved.
